Gast K, Snyder T
Department of Gynecology and Obstetrics, KUMC-KC.
Kans Med. 1990 Jul;91(7):201-8.
Substantial evidence exists to suggest that the use of oral contraceptives alters the risk for some types of cancer. Use of oral contraceptives for one year or more will reduce the risk of endometrial cancer and epithelial ovarian cancer by 50%, with the protective effect lasting for at least 10 years. The risk for developing cervical cancer in women who have used oral contraceptives appears to be slightly increased, although two independent studies actually found a protective effect associated with oral contraceptive use. The protective effect was probably related to the increased screening frequency found in oral contraceptive users and not related to a biologically protective effect. Therefore, women should be encouraged to undergo regular Pap tests. Data regarding breast cancer, in general, show no increased risk associated with oral contraceptive use. The latency associated with the development of breast cancer does not allow a definitive conclusion, and further study will be required. Oral contraceptives appear to increase the risk for developing benign hepatocellular adenoma, but not hepatocellular carcinoma.
有大量证据表明,口服避孕药的使用会改变某些类型癌症的风险。使用口服避孕药一年或更长时间可将子宫内膜癌和上皮性卵巢癌的风险降低50%,且保护作用至少持续10年。使用口服避孕药的女性患宫颈癌的风险似乎略有增加,不过两项独立研究实际上发现口服避孕药的使用具有保护作用。这种保护作用可能与口服避孕药使用者筛查频率增加有关,而非生物学上的保护作用。因此,应鼓励女性定期进行巴氏试验。总体而言,关于乳腺癌的数据显示,口服避孕药的使用不会增加风险。乳腺癌发生的潜伏期使得无法得出明确结论,还需要进一步研究。口服避孕药似乎会增加患良性肝细胞腺瘤的风险,但不会增加患肝细胞癌的风险。